Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Seeking Alpha • Dec 8, 2025

Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?

Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 8, 2025

Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 5, 2025

Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?

The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 5, 2025

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

PRNewsWire • Nov 20, 2025

Theravance Biopharma to Participate in Upcoming Investor Conferences

DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside ChatDate: Thursday, December 4, 2025 Time: 8:20-8:40 AM ET Webcast Oppenheimer Movers in Rare Disease Summit Location: New York, NY Format: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025 Time: 2:15-2:45 PM ET Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.

PRNewsWire • Nov 19, 2025

Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 19, 2025

Here's Why Shares in Theravance Biopharma Exploded Today

Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones.

The Motley Fool • Nov 11, 2025

Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript

Theravance Biopharma, Inc. ( TBPH ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ellen Horste - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, good afternoon.

Seeking Alpha • Nov 11, 2025

Theravance's Q3 Earnings Surpass Estimates, Revenues Match

TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.

Zacks Investment Research • Nov 11, 2025